Newsletter Tool

Whitepaper: How AI-driven drug discount management benefits drug manufacturers' financial health

This whitepaper explores how duplicate discounts from drug discount programs adversely impact drug manufacturer finances, why the expansion of the 340B program has magnified the problem and stakeholder frustrations, and more. Download now.

Today's Rundown

Featured Story

Dr. Reddy’s launches extended-release rival to $200M Pfizer drug

By Nick Paul Taylor

Dr. Reddy's Laboratories is gunning for Pfizer’s extended-release overactive bladder treatment Toviaz, introducing a therapeutic generic equivalent that could threaten more than $200 million in revenues.

Webinar: The New Role of Social Networks in Patient Education

Thursday, August 4, 2022 | 2:00pm ET / 11:00am PT

Whether developing a drug for a new indication, preparing for the launch of a new drug, or building awareness of an existing therapy, one thing is clear; you have to break through the noise and engage patients directly at every stage of the process to be successful. Join this webinar for insights into the increasingly important role social networks play in patient education and engagement. Register now.

Chiesi enlists support for nose-to-brain biologic delivery push

By Nick Paul Taylor

A European Union-backed initiative has assembled a team to develop a nose-to-brain biologics delivery device for neonates, enlisting medtech company Eveon and other groups to support Chiesi Farmaceutici.

Biora, with spin on Xeljanz nearing the clinic, posts data on its targeted gut drug delivery device

By Nick Paul Taylor

Biora Therapeutics has generated more evidence that the delivery device behind its spin on Xeljanz can get drugs safely to targets in the gut, regardless of whether the recipient is fed or fasted.

Take 2: Hanmi relaunches liver drug after boosting bioavailability

By Nick Paul Taylor

Hanmi Pharmaceutical has relaunched its liver function drug after using its microemulsion technology to improve the absorption rate, thereby addressing a limitation of the original formulation.

'The Top Line' podcast: Biotech's beef with FDA's accelerated approval reforms, plus this week's headlines

By Teresa Carey

This week on "The Top Line," we discuss proposed reforms to FDA’s accelerated approval program—and what the biotech industry has to say about them. The Fierce team gets creative with our own biopharma competition. Plus, news from Vertex, Biogen and Eisai, Orchestra and more.

Article Download: Formulation Strategies When Transitioning From Vial to PFS

Prefilled syringes (PFS) can help cut manufacturing and product costs and offers significant benefits to the physician and patient. Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Download Now.